Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease
Shorena Janelidze, Charlotte E. Teunissen, Henrik Zetterberg, et al.
JAMA Neurology (2021) Vol. 78, Iss. 11, pp. 1375-1375
Open Access | Times Cited: 291

Showing 1-25 of 291 citing articles:

Hallmarks of neurodegenerative diseases
David M. Wilson, Mark Cookson, Ludo Van Den Bosch, et al.
Cell (2023) Vol. 186, Iss. 4, pp. 693-714
Open Access | Times Cited: 679
The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease
Oskar Hansson, Rebecca M. Edelmayer, Adam L. Boxer, et al.
Alzheimer s & Dementia (2022) Vol. 18, Iss. 12, pp. 2669-2686
Open Access | Times Cited: 329
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Clifford R. Jack, J. Scott Andrews, Thomas G. Beach, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 8, pp. 5143-5169
Open Access | Times Cited: 275
Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease
Shorena Janelidze, Divya Bali, Nicholas J. Ashton, et al.
Brain (2022) Vol. 146, Iss. 4, pp. 1592-1601
Open Access | Times Cited: 241
Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring
Nicholas J. Ashton, Shorena Janelidze, Niklas Mattsson, et al.
Nature Medicine (2022) Vol. 28, Iss. 12, pp. 2555-2562
Open Access | Times Cited: 219
Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility
Thomas K. Karikari, Nicholas J. Ashton, Gunnar Brinkmalm, et al.
Nature Reviews Neurology (2022) Vol. 18, Iss. 7, pp. 400-418
Closed Access | Times Cited: 195
Blood‐based biomarkers for Alzheimer's disease
Antoine Leuzy, Niklas Mattsson, Sebastian Palmqvist, et al.
EMBO Molecular Medicine (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 192
Blood biomarkers for Alzheimer’s disease in clinical practice and trials
Oskar Hansson, Kaj Blennow, Henrik Zetterberg, et al.
Nature Aging (2023) Vol. 3, Iss. 5, pp. 506-519
Open Access | Times Cited: 174
Solving neurodegeneration: common mechanisms and strategies for new treatments
Lauren K. Wareham, Shane A. Liddelow, Sally Temple, et al.
Molecular Neurodegeneration (2022) Vol. 17, Iss. 1
Open Access | Times Cited: 169
Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease
Michael J. Pontecorvo, Ming Lu, Samantha Burnham, et al.
JAMA Neurology (2022) Vol. 79, Iss. 12, pp. 1250-1250
Open Access | Times Cited: 135
Brain-derived tau: a novel blood-based biomarker for Alzheimer’s disease-type neurodegeneration
Fernándo González‐Ortiz, Michael Turton, Przemyslaw Radoslaw Kac, et al.
Brain (2022) Vol. 146, Iss. 3, pp. 1152-1165
Open Access | Times Cited: 128
Mental health care for older adults: recent advances and new directions in clinical practice and research
Charles F. Reynolds, Dilip V. Jeste, Perminder S. Sachdev, et al.
World Psychiatry (2022) Vol. 21, Iss. 3, pp. 336-363
Open Access | Times Cited: 123
Plasma Aβ42/40 ratio, p‐tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross‐sectional and longitudinal study in the AIBL cohort
Pratishtha Chatterjee, Steve Pedrini, James D. Doecke, et al.
Alzheimer s & Dementia (2022) Vol. 19, Iss. 4, pp. 1117-1134
Open Access | Times Cited: 116
Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance
Alexa Pichet Binette, Shorena Janelidze, Nicholas Cullen, et al.
Alzheimer s & Dementia (2022) Vol. 19, Iss. 4, pp. 1403-1414
Open Access | Times Cited: 113
Blood-based biomarkers for Alzheimer’s disease: Current state and future use in a transformed global healthcare landscape
Harald Hampel, Yan Hu, Jeffrey L. Cummings, et al.
Neuron (2023) Vol. 111, Iss. 18, pp. 2781-2799
Open Access | Times Cited: 104
Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light
Suzanne E. Schindler, Thomas K. Karikari, Nicholas J. Ashton, et al.
Neurology (2022) Vol. 99, Iss. 3
Open Access | Times Cited: 101
Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease
Antoine Leuzy, Ruben Smith, Nicholas Cullen, et al.
JAMA Neurology (2021) Vol. 79, Iss. 2, pp. 149-149
Open Access | Times Cited: 99
Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads
Gemma Salvadó, Rik Ossenkoppele, Nicholas J. Ashton, et al.
EMBO Molecular Medicine (2023) Vol. 15, Iss. 5
Open Access | Times Cited: 90
Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias
Simone Baiardi, Corinne Quadalti, Angela Mammana, et al.
Alzheimer s Research & Therapy (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 87
The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease: a literature review
Abby L. Brand, Paige E. Lawler, James G. Bollinger, et al.
Alzheimer s Research & Therapy (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 80
Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment
Yan Hu, Kristopher M. Kirmess, Matthew R. Meyer, et al.
JAMA Network Open (2022) Vol. 5, Iss. 4, pp. e228392-e228392
Open Access | Times Cited: 76
Heterogeneity in Alzheimer's Disease Diagnosis and Progression Rates: Implications for Therapeutic Trials
Ranjan Duara, Warren Barker
Neurotherapeutics (2022) Vol. 19, Iss. 1, pp. 8-25
Open Access | Times Cited: 67
Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios
Shorena Janelidze, Nicolas R. Barthélemy, Yingxin He, et al.
JAMA Neurology (2023) Vol. 80, Iss. 5, pp. 516-516
Open Access | Times Cited: 66
Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force
Davide Angioni, Julien Delrieu, Oskar Hansson, et al.
The Journal of Prevention of Alzheimer s Disease (2022)
Open Access | Times Cited: 64
Equivalence of plasma p‐tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease
Joseph Therriault, Stijn Servaes, Cécile Tissot, et al.
Alzheimer s & Dementia (2023) Vol. 19, Iss. 11, pp. 4967-4977
Open Access | Times Cited: 64
Page 1 - Next Page

Scroll to top